Dyskeratosis Congenita — Research Summary
Printed from RareWays (rareways.com.au) on 24 September 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Disease mutations in the N-terminal extension and α2'-helix of dyskerin do not abolish dimerization but disrupt binding to the telomerase RNA.
Qin Jian et al. — RNA (New York, N.Y.) (16 September 2026)
https://pubmed.ncbi.nlm.nih.gov/42538130/
- 2.
The potential of gene therapy to rescue telomeric and extratelomeric defects in X-linked dyskeratosis congenita.
Llorente-Arroyo Diego et al. — Molecular therapy. Advances (10 September 2026)
https://pubmed.ncbi.nlm.nih.gov/42564579/
- 3.
RTEL1 mutation modifies dyskeratosis congenita caused by a telomerase RNA template mutation.
Deimler Nathaniel et al. — Nature communications (26 August 2026)
https://pubmed.ncbi.nlm.nih.gov/42649225/
- 4.
Retinopathy in Dyskeratosis Congenita and Related Telomere Biology Disorders: Short Telomere Associated Retinopathy (STAR).
Jeng-Miller Karen W et al. — Ophthalmology. Retina (19 August 2026)
https://pubmed.ncbi.nlm.nih.gov/42617951/
- 5.
Outcomes of Dyskeratosis Congenita: Results From the Canadian Inherited Marrow Failure Registry.
Al Nuaimi Mohammed et al. — Journal of pediatric hematology/oncology (1 August 2026)
https://pubmed.ncbi.nlm.nih.gov/42267950/
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Dyskeratosis Congenita
Dyskeratosis congenita is a rare inherited condition caused by problems with telomeres, the protective ends of chromosomes. It classically affects the bone marrow, skin and nails, and can involve the lungs and liver, with a raised risk of some cancers. Care involves regular monitoring, treatment of low blood counts and, for some people, a bone marrow transplant.
Most Recent Research
The H/ACA ribonucleoprotein complex component dyskerin is essential for the biogenesis of H/ACA RNAs, including the human telomerase RNA (hTR). The N-terminal extension and α2' helix of dyskerin are hotspots for disease-associated mutations linked to X-linked dyskeratosis congenita (X-DC), a premature aging disorder. Some of these mutations disrupt dyskerin-hTR interactions, leading to hTR destabilization and reduced telomerase activity. Cryo-EM structures of human telomerase have shown that the N-terminal extension and α2' helix participate in dyskerin dimerization. However, biochemical evidence for dyskerin dimerization is still lacking, and it remains unclear whether mutations in these regions impair hTR binding by disrupting dimerization. Here, we provide the first biochemical evidence that dyskerin undergoes dimerization. We further demonstrate that dimerization is RNA independent and not abolished by disease mutations in the N-terminal extension or α2' helix. Instead, these mutations impair hTR binding. Our findings offer new mechanistic insight into how mutations in the dyskerin N-terminal extension and α2' helix contribute to the pathogenesis of X-DC.
Common Questions
What is Dyskeratosis Congenita?
Dyskeratosis congenita is a rare inherited condition caused by problems with telomeres, the protective ends of chromosomes. It classically affects the bone marrow, skin and nails, and can involve the lungs and liver, with a raised risk of some cancers. Care involves regular monitoring, treatment of low blood counts and, for some people, a bone marrow transplant.
How many clinical trials are available for Dyskeratosis Congenita?
RareWays currently indexes 13 clinical trials for Dyskeratosis Congenita, of which 7 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Dyskeratosis Congenita come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Dyskeratosis Congenita.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.